Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
FEBS J. 2012 Apr;279(7):1198-208. doi: 10.1111/j.1742-4658.2012.08512.x. Epub 2012 Feb 23.
Recently, microRNA (miRNA)-mediated RNA interference has been developed as a useful tool in gene function analysis and gene therapy. A major obstacle in miRNA-mediated RNAi is cellular delivery, which requires an efficient and flexible delivery system. The self-assembly of the MS2 bacteriophage capsids has been used to develop virus-like particles (VLPs) for RNA and drug delivery. However, MS2 VLP-mediated miRNA delivery has not yet been reported. We therefore used an Escherichia coli expression system to produce the pre-miR 146a contained MS2 VLPs, and then conjugated these particles with HIV-1 Tat(47-57) peptide. The conjugated MS2 VLPs effectively transferred the packaged pre-miR146a RNA into various cells and tissues, with 0.92-14.76-fold higher expression of miR-146a in vitro and about two-fold higher expression in vivo, and subsequently suppressed its targeting gene. These findings suggest that MS2 VLPs can be used as a novel vehicle in miRNA delivery systems, and may have applications in gene therapy.
最近,微小 RNA(miRNA)介导的 RNA 干扰已成为基因功能分析和基因治疗的有用工具。miRNA 介导的 RNAi 的主要障碍是细胞内传递,这需要高效和灵活的传递系统。MS2 噬菌体衣壳的自组装已被用于开发用于 RNA 和药物传递的病毒样颗粒(VLPs)。然而,尚未报道 MS2 VLP 介导的 miRNA 传递。因此,我们使用大肠杆菌表达系统生产含有 MS2 VLP 的 pre-miR146a,并将这些颗粒与 HIV-1 Tat(47-57)肽缀合。缀合的 MS2 VLP 有效地将包装的 pre-miR146a RNA 转染到各种细胞和组织中,体外 miR-146a 的表达提高了 0.92-14.76 倍,体内表达提高了约 2 倍,随后抑制了其靶基因。这些发现表明 MS2 VLP 可作为 miRNA 传递系统中的新型载体,并可能在基因治疗中得到应用。